Lyell Immunopharma Inc（LYEL）财务数据LYELLyell Immunopharma Inc

Evaluating the bottom line, Lyell Immunopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1183425.00%, while the net margin is -1118875.00%. These profitability ratios, combined with a Return on Equity (ROE) of -93.28%, provide a clear picture of how effectively LYEL converts its operational activities into shareholder value.

In the context of the broader market, LYEL competes directly with industry leaders such as BIOA and RCKT. With a market capitalization of $378.19M, it holds a leading position in the sector. When comparing efficiency, LYEL's gross margin of 100.00% stands against BIOA's 100.00% and RCKT's N/A. Such benchmarking helps identify whether Lyell Immunopharma, Inc. is trading at a premium or discount relative to its financial performance.

Lyell Immunopharma has a gross margin of 100%, indicating no cost of goods sold, which is a positive sign for potential profitability in the future. However, the company has been reporting significant net losses, with a Q4 2025 loss of $140.7 million.